---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-090722"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T12:59:01.263194+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Enanta reports Q3 net loss $22.7M, cash $272.6M; RSV trials on track

## Summary
- Revenue $18.0M (royalty from AbbVie's MAVYRET); net loss $22.7M ($1.07 EPS) vs $39.1M loss a year ago.
- Cash, equivalents and securities $272.6M at June 30, 2024; expects runway through Q3 FY2027.
- Completed enrollment in RSVPEDs Phase 2 study of zelicapavir in pediatric RSV; topline data expected Q4 2024.
- EDP-323 Phase 2a challenge study completed; topline data expected late Q3 2024.
- Legal expenses increased due to patent infringement lawsuit against Pfizer; no Q3 earnings call.

## SEC filing metadata
- accession: 0000950170-24-090722
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017024090722/0000950170-24-090722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017024090722/enta-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-090722
- JSON: https://secwatch.observer/filing/0000950170-24-090722.json
- Plain text: https://secwatch.observer/filing/0000950170-24-090722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.